We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
Read MoreHide Full Article
Immunovant, Inc. (IMVT - Free Report) reported a net loss of 35 cents per share in the second quarter of fiscal 2022 (ended Sep 30, 2021), wider than the Zacks Consensus Estimate of a loss of 26 cents. In the year-ago quarter, the company reported a loss of 25 cents.
Currently, the company does not have any approved product in its portfolio. As a result, it is yet to generate revenues.
Shares of Immunovant have plunged 81.4% so far this year compared with the industry’s decrease of 12.1%.
Image Source: Zacks Investment Research
Quarter in Detail
In the reported quarter, research and development (R&D) expenses were $21.4 million, up 78.3% from the year-ago quarter. The year-over-year surge was due to increased personnel-related expenses and higher costs related to clinical activities.
General and administrative (G&A) expenses were $16.3 million in the reported quarter, up 81.1% on a year-over-year basis. The increase was primarily due to higher financial advisory fees, legal and other costs, and increased personnel-related expenses.
As of Sep 30, 2021, the company had cash balance of approximately $559 million compared with $379 million as of Jun 30, 2021.
Pipeline Update
Immunovant is developing its lead pipeline candidate, IMVT-1401, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. The company is developing IMVT-1401 with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”).
A pivotal study evaluating IMVT-1401 for treating MG is expected to begin in 2022. In July 2021, the FDA granted an Orphan Drug designation to IMVT-1401 for the treatment of MG.
Immunovant plans to resume the development of IMVT-1401 for WAIHA and TED in the upcoming quarters.
We remind investors, that in February 2021, the company voluntarily paused dosing in ASCEND GO-2 – a phase IIb study in TED, and in ASCEND-WAIHA – a phase II study on IMVT-1401 in WAIHA due to elevated total cholesterol and LDL levels observed in patients who were treated with IMVT-1401.
We note that Johnson & Johnson (JNJ - Free Report) is also developing nipocalimab in mid-and late-stage studies for treating WAIHA, generalized MG and other rare diseases.
Immunovant, Inc. Price, Consensus and EPS Surprise
Image: Bigstock
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
Immunovant, Inc. (IMVT - Free Report) reported a net loss of 35 cents per share in the second quarter of fiscal 2022 (ended Sep 30, 2021), wider than the Zacks Consensus Estimate of a loss of 26 cents. In the year-ago quarter, the company reported a loss of 25 cents.
Currently, the company does not have any approved product in its portfolio. As a result, it is yet to generate revenues.
Shares of Immunovant have plunged 81.4% so far this year compared with the industry’s decrease of 12.1%.
Quarter in Detail
In the reported quarter, research and development (R&D) expenses were $21.4 million, up 78.3% from the year-ago quarter. The year-over-year surge was due to increased personnel-related expenses and higher costs related to clinical activities.
General and administrative (G&A) expenses were $16.3 million in the reported quarter, up 81.1% on a year-over-year basis. The increase was primarily due to higher financial advisory fees, legal and other costs, and increased personnel-related expenses.
As of Sep 30, 2021, the company had cash balance of approximately $559 million compared with $379 million as of Jun 30, 2021.
Pipeline Update
Immunovant is developing its lead pipeline candidate, IMVT-1401, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. The company is developing IMVT-1401 with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”).
A pivotal study evaluating IMVT-1401 for treating MG is expected to begin in 2022. In July 2021, the FDA granted an Orphan Drug designation to IMVT-1401 for the treatment of MG.
Immunovant plans to resume the development of IMVT-1401 for WAIHA and TED in the upcoming quarters.
We remind investors, that in February 2021, the company voluntarily paused dosing in ASCEND GO-2 – a phase IIb study in TED, and in ASCEND-WAIHA – a phase II study on IMVT-1401 in WAIHA due to elevated total cholesterol and LDL levels observed in patients who were treated with IMVT-1401.
We note that Johnson & Johnson (JNJ - Free Report) is also developing nipocalimab in mid-and late-stage studies for treating WAIHA, generalized MG and other rare diseases.
Immunovant, Inc. Price, Consensus and EPS Surprise
Immunovant, Inc. price-consensus-eps-surprise-chart | Immunovant, Inc. Quote
Zacks Rank & Stocks to Consider
Immunovant currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector include Amicus Therapeutics, Inc. (FOLD - Free Report) and Athenex, Inc. , both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amicus Therapeutics’ loss per share estimates have narrowed 1.3% for 2021 and 37.5% for 2022 over the past 60 days.
Athenex’s loss per share estimates have narrowed 9% for 2021 and 9.2% for 2022 over the past 60 days.